Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

J Elliott

Physician Assistant, Medical Lansing, MI Physician Assistant

NPI 1841299617 CMS profile 11199006

416 S Creyts Rd, Lansing, MI 48917

Open in the dashboard

General payments

$6,239

349 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, J Elliott of Lansing, MI is reported in the CMS Open Payments database as having received $6,239 across 349 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,814 93
2024 General $2,468 123
2023 General $1,720 120
2022 General $237 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • J Elliott
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to J Elliott were reported at $1,814. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year J Elliott Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $0 $156 $41–$563 $132
2022 $237 $185 $55–$649 $149
2023 $1,720 $199 $58–$717 $160
2024 $2,468 $206 $62–$740 $164
2025 $1,814 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Janssen Biotech, Inc. $820 35 payments
  2. Lilly USA, LLC $568 24 payments
  3. AbbVie, Inc. $547 26 payments
  4. Amgen Inc. $523 24 payments
  5. Genzyme Corporation $465 22 payments
  6. Dermavant Sciences, Inc. $435 50 payments
  7. E.R. Squibb & Sons, L.L.C. $405 22 payments
  8. Sun Pharmaceutical Industries Inc. $392 30 payments
  9. Regeneron Healthcare Solutions, Inc. $355 11 payments
  10. Arcutis Biotherapeutics, Inc. $302 16 payments
  11. Other $1,427 89 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $5,951 344 payments
  2. Education $288 5 payments
Products named General payments · program years 2022–2025
  1. TREMFYA $820 35 payments
  2. VTAMA $602 65 payments
  3. DUPIXENT Immunology $556 26 payments
  4. Otezla $523 24 payments
  5. SOTYKTU $405 22 payments
  6. TALTZ $342 18 payments
  7. RINVOQ $322 14 payments
  8. DUPIXENT Inflammation And Immunology $262 8 payments
  9. Zoryve $243 13 payments
  10. OLUMIANT $231 7 payments
  11. Other $2,576 160 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

963

Median for Physician Assistant: 241

Drug cost

$343,833

Median for Physician Assistant: $4,110

Branded share of claims

13.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Enbrel Etanercept Brand 15 $108,611
Dupixent Pen Dupilumab Brand 28 $107,099
Otezla Apremilast Brand 21 $100,318
Clobetasol Propionate Generic 149 $5,890
Clindamycin Phosphate Generic 67 $3,488
Fluorouracil Generic 54 $3,206
Betamethasone Dipropionate Generic 66 $3,057
Ciclopirox Generic 45 $2,002
Azelaic Acid Generic 14 $1,704
Metronidazole Generic 16 $1,641

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$55,944

Of which drugs: $16

Medicare patients

338

Average age 73

Services billed

2,213

126 women, 212 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 44%
Diabetes 28%
Chronic kidney disease 21%
Ischemic heart disease 20%
Atrial fibrillation 17%
Cancer 17%
Depression 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 12 37 $16

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $166
  • Regeneron Healthcare Solutions, Inc. $158
$323 28 —
VTAMA
  • Dermavant Sciences, Inc. $304
$304 — —
TREMFYA
  • Janssen Biotech, Inc. $299
$299 — —
Otezla
  • Amgen Inc. $215
$215 21 —
Zoryve
  • Arcutis Biotherapeutics, Inc. $176
$176 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

349 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record